TWC
ITCI

TD Waterhouse Canada’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

TD Waterhouse Canada’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24
Closed -$1.5K – 1840
2022
Q1 		$1.5K Hold
24
– – ﹤0.01% 1627
2021
Q4 		$1.07K Buy
+24
New +$1.01K ﹤0.01% 1650

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TD Waterhouse Canada's ITCI Position: Q2 2022 in Review

TD Waterhouse Canada sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2022, closing a stake of 24 shares — an estimated $1.5K sold.

TD Waterhouse Canada first reported a position in ITCI in Q4 2021 and held it in 2 quarters. The position peaked at $1.5K in Q1 2022. 266 funds tracked by Wall St. Rank hold ITCI as of Q2 2022.

  • TD Waterhouse Canada reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2022 after selling out during the quarter.
  • TD Waterhouse Canada sold 24 Intra-Cellular Therapies Inc. shares in Q2 2022, an estimated $1.5K.
  • TD Waterhouse Canada first reported a position in Intra-Cellular Therapies Inc. in Q4 2021 and held it in 2 quarters.
  • TD Waterhouse Canada's Intra-Cellular Therapies Inc. position peaked at $1.5K in Q1 2022.
  • 266 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2022.

Based on TD Waterhouse Canada's 13F filing for Q2 2022, filed 13 Nov 2023.